Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;6(4):753-62.
doi: 10.1007/s12072-011-9322-7. Epub 2011 Nov 30.

Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis

I-Cheng Lee  1   2 , Teh-Ia Huo  1   3 , Yi-Hsiang Huang  4   5 , Yee Chao  6 , Chung-Pin Li  1 , Pui-Ching Lee  1 , Jen-Huey Chiang  7 , Chien-Wei Su  1   2 , Keng-Hsin Lan  1   3 , Chih-Ming Yang  1 , Jaw-Ching Wu  8   2 , Han-Chieh Lin  1 , Shou-Dong Lee  1
Affiliations

Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis

I-Cheng Lee et al. Hepatol Int. 2012 Oct.

Abstract

Background: In Asian countries, transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients with extra-hepatic metastasis in the absence of main portal vein thrombosis. However, its survival benefit is unclear. The study aimed to analyze the role of TACE in patients with metastatic HCC.

Methods: From 2002 to 2009, 2,165 consecutive HCC patients were retrospectively reviewed. Of the 893 Barcelona Clinic Liver Cancer stage C patients, 105 who had extra-hepatic metastasis on initial presentation without main portal vein thrombosis were enrolled, including 46 who received TACE (TACE group) and 59 who received supportive treatment (control group). Factors associated with survival were evaluated by multivariate analysis. Survival between the two groups was compared by propensity score matching analysis.

Results: Median survival in the TACE and control groups was 6.6 and 3.2 months, respectively (p < 0.001). By multivariate analysis, TACE [hazard ratio (HR) = 0.476, p = 0.002], tumor size >10 cm (HR = 1.606, p = 0.045), and alpha-fetoprotein (AFP) >2,000 ng ml(-1) (HR = 1.599, p = 0.037) were factors associated with survival. After propensity score matching analysis, a better survival was noted in the TACE group (median survival 4.0 vs. 3.0 months, p = 0.029). Subgroup analysis showed that patients with tumor size ≤10 cm and AFP levels ≤2,000 ng ml(-1) had the best survival from TACE. Smaller tumor size is the only independent predictor for survival longer than 6 months in patients receiving TACE.

Conclusions: TACE provides survival benefit for metastatic HCC patients. Prospective randomized controlled trials are warranted to delineate the role of combining TACE with sorafenib or other treatment for metastatic HCC.

Keywords: Hepatocellular carcinoma (HCC); Metastasis; Propensity score; Survival; Transarterial chemoembolization (TACE).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stat Med. 1998 Oct 15;17(19):2265-81 - PubMed
    1. Hepatology. 2011 Mar;53(3):1020-2 - PubMed
    1. J Gastroenterol Hepatol. 2005 May;20(5):765-71 - PubMed
    1. J Hepatol. 2010 Jul;53(1):108-17 - PubMed
    1. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed

LinkOut - more resources